The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today